Back to top
more

Zoetis (ZTS)

(Delayed Data from NYSE)

$159.70 USD

159.70
4,849,556

+1.28 (0.81%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $159.76 +0.06 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).

Sheraz Mian headshot

Top Stock Reports for Bank of America, Toyota Motor & AT&T

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), Toyota Motor Corporation (TM) and AT&T Inc. (T).

TAK vs. ZTS: Which Stock Is the Better Value Option?

by Zacks Equity Research

TAK vs. ZTS: Which Stock Is the Better Value Option?

Zoetis' (ZTS) Q2 Earnings Miss Estimates, Revenues Up

by Zacks Equity Research

Zoetis' (ZTS) earnings miss estimates in second-quarter 2022. The revenues beat estimates owing to the strong uptake of the company's companion animal portfolio products.

Zoetis (ZTS) Misses Q2 Earnings Estimates

by Zacks Equity Research

Zoetis (ZTS) delivered earnings and revenue surprises of -1.64% and 1.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

TAK vs. ZTS: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

TAK vs. ZTS: Which Stock Is the Better Value Option?

What's in the Cards for Bausch Health (BHC) Q2 Earnings?

by Zacks Equity Research

An update on the IPO of Solta Medical and regular top-line and bottom-line numbers will grab investors' attention when Bausch Health (BHC) reports Q2 results.

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.39% and 14.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Viatris (VTRS) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on top-line and bottom-line numbers when Viatris (VTRS) reports second-quarter results.

Exelixis (EXEL) to Post Q2 Earnings: What is in the Cards?

by Zacks Equity Research

Investors will likely focus on the demand for Cabometyx and pipeline updates when Exelixis (EXEL) reports Q2 results. Operating expenses might have jumped.

Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis (ZTS) is set to report impressive earnings and revenues and provide an update on its pipeline when it releases second-quarter 2022 results.

Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ASRT vs. ZTS: Which Stock Is the Better Value Option?

Why Zoetis (ZTS) Could Beat Earnings Estimates Again

by Zacks Equity Research

Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Aurinia (AUPH) Moves 13.3% Higher: Will This Strength Last?

by Zacks Equity Research

Aurinia (AUPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

ASRT or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ASRT vs. ZTS: Which Stock Is the Better Value Option?

ASRT vs. ZTS: Which Stock Is the Better Value Option?

by Zacks Equity Research

ASRT vs. ZTS: Which Stock Is the Better Value Option?

ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ASRT vs. ZTS: Which Stock Is the Better Value Option?

Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis' (ZTS) earnings and revenues trump estimates in the first quarter of 2022.

Zoetis (ZTS) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Zoetis (ZTS) delivered earnings and revenue surprises of 8.20% and 0.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More

by Zacks Equity Research

Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.

Is a Beat in Store for Zoetis (ZTS) This Earnings Season?

by Zacks Equity Research

Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases first-quarter 2022 results.

Zoetis (ZTS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tenet Healthcare (THC) Q1 Earnings Beat Mark, Surge Y/Y

by Zacks Equity Research

Tenet Healthcare (THC) Q1 earnings gain from a healthy revenue stream, reduced expenses and operational efficiency.

Why the Earnings Surprise Streak Could Continue for Zoetis (ZTS)

by Zacks Equity Research

Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.